SEC filing record
Primary Source · SEC.gov

X4 Pharmaceuticals, Inc

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2025-08-25Last filing 2025-08-25

Raised

$85M

Investors

18

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

X4 Pharmaceuticals, Inc is a Delaware corporation that first filed a Form D on August 11, 2014 and most recently amended it on August 25, 2025 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. X4 Pharmaceuticals, Inc reported $84,999,985 sold from 18 investors of a $84,999,985 total offering as of the Form D filed August 25, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names STIFEL, NICOLAUS & COMPANY, INCORPORATED (CRD 793), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $3,300,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 61 North Beacon Street, 4th Floor, Boston, MA 02134.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001501697
Entity NameX4 Pharmaceuticals, Inc
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address61 North Beacon Street, 4th Floor, Boston, MA 02134
Phone(857) 529-8300
Former NamesArsanis, Inc. (until March 13, 2019)
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateAugust 13, 2025
Filing DateAugust 25, 2025
Accession Number0001470831-25-000145
Total Offering Amount$84,999,985
Total Amount Sold$84,999,985
Amount Remaining$0
Total Investors18
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$3,300,000 (to STIFEL, NICOLAUS & COMPANY, INCORPORATED)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)MA
Amendment Count9 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Aug 25, 2025

Critical / warning

0 / 0

1 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

6

lapsed, closed

Latest event New filer · Aug 25, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the X Pharmaceuticals family: 2 vehicles across 1 generation; Beneficially owned by MORGAN STANLEY · full family and the filing behind each link in the terminal

Investor

  • The full fund family and 1 related vehicle (parallel, feeder, successor, sibling series) with the filing that shows each link
  • 1 filing event with values and deltas, latest 2025-08-25, and alerts on the next one
  • 6 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2025-08-25: 4 related persons added and 6 removed against the filing of 2023-06-01; 10 now listed. The names are in the Terminal feed.

Adam Craig

Executive Officer, Director · BOSTON, MA

John Volpone

Executive Officer · BOSTON, MA

Christophe Arbet-Engels

Executive Officer · BOSTON, MA

Mark Baldry

Executive Officer · BOSTON, MA

Mary DiBiase

Executive Officer · BOSTON, MA

David Kirske

Executive Officer · BOSTON, MA

Gary J. Bridger

Director · BOSTON, MA

Francoise J. De Craecker

Director · BOSTON, MA

Murray W. Stewart

Director · BOSTON, MA

Michael S. Wyzga

Director · BOSTON, MA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

STIFEL, NICOLAUS & COMPANY, INCORPORATEDCRD 793 on BrokerCheck

Associated broker-dealer: None · ST. LOUIS, MO · Soliciting in all states and outside the United States

Questions About X4 Pharmaceuticals, Inc

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is X4 Pharmaceuticals, Inc?

X4 Pharmaceuticals, Inc is a Delaware corporation that filed a Form D with the SEC on August 25, 2025 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is X4 Pharmaceuticals, Inc legit?

AltStreet does not rate legitimacy; it reports the public record. X4 Pharmaceuticals, Inc filed a Form D with the SEC on August 25, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $84,999,985 sold to 18 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is X4 Pharmaceuticals, Inc registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that X4 Pharmaceuticals, Inc claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has X4 Pharmaceuticals, Inc raised?

X4 Pharmaceuticals, Inc reported $84,999,985 sold from 18 investors of a $84,999,985 total offering as of the Form D filed August 25, 2025.

Who can invest in X4 Pharmaceuticals, Inc?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in X4 Pharmaceuticals, Inc?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling X4 Pharmaceuticals, Inc and how are they paid?

The Form D names STIFEL, NICOLAUS & COMPANY, INCORPORATED (CRD 793), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $3,300,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind X4 Pharmaceuticals, Inc?

The Form D lists 10 related persons: Adam Craig, executive officer, director; John Volpone, executive officer; Christophe Arbet-Engels, executive officer; Mark Baldry, executive officer; Mary DiBiase, executive officer; David Kirske, executive officer; Gary J. Bridger, director; Francoise J. De Craecker, director, and 2 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is X4 Pharmaceuticals, Inc located?

The issuer's address on its SEC filings is 61 North Beacon Street, 4th Floor, Boston, MA 02134. Its phone number of record is 857-529-8300. It is organized under the laws of Delaware.

How long is the X4 Pharmaceuticals, Inc offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.

What is X4 Pharmaceuticals, Inc's revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.